pharmaceut new cgrp survey deep dive
increment posit agn/abbv less bearish teva rais
conduct new survey neurologist treat migrain coincid sever major cgrp
market develop cgrp market implic multipl cover non-cov stock
focu primarili agn/abbv ubrelvi botox atogep ii teva ajovi
agn/abbv come away increment posit market opportun oral cgrp
less concern around botox migrain share loss rais target
updat pro-forma forecast still question around out-year growth
increment confid near-term trend overal teva less bearish
ajovi outlook one compani two import growth driver
sale off-set concern around lack growth/opioid still
guidanc ajovi rais estim expect support near-term autoinjector launch
recent price increas highlight key survey takeaway full survey result
exhibit also updat cgrp product market model exhibit
sever move part prevent cgrp market botox ajovi stand two
winner survey physician expect increas botox migrain usag
next month decreas versu major expect chang
improv last year ratio increas vs decreas indic greater
durabl previous expect despit robust growth expect prevent cgrp
market physician expect increas cgrp usag next month ajovi one
clear winner teva pend autoinjector launch expect drive net bp increas
market share exhibit lundbeck eptinezumab pdufa expect take share
physician see meaning place market acut oral cgrp bode well
recent launch ubrelvi futur atogep launch ubrelvi launch januari
alreadi reach weekli third week launch per survey physician indic
like prescrib oral cgrp acut migrain total migrain patient
greatest use among chronic migrain patient exhibit somewhat surpris
model greatest use episod migrain headach day per month rais peak
penetr estim acut oral cgrp still leav meaning room upsid
continu expect ubrelvi split market rimegep pdufa
reimburs remain one biggest swing factor cgrp heavi discount
sampl character earli cgrp market format three rel similar therapi
compet share per survey one product appear edg respect
reimbursement/access aimovig ajovi emgal botox receiv similar difficulti
rate exhibit expect market remain competit also forecast modest improv
gross-to-net go forward key question whether patient reimburs
acut prevent cgrp therapi concurr
sever import updat watch next month lundbeck eptinezumab
pdufa friday eptinezumab iv-administ prevent cgrp develop aldr
subsequ acquir lundbeck ii ajovi autoinjector launch come month fda
approv receiv late jan iii rimegep pdufa expect compet
ubrelvi iv top-line data phase atogep clinic trial episod
migrain data chronic migrain data
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
pharmaceut new cgrp survey deep dive
updat look cgrp competit landscap new survey
implic sever compani within coverag
ran new survey refresh cgrp market model coincid sever new
product launch rapidli evolv cgrp market larg grow market
allergan/abbvi ubrelvi botox atogep teva ajovi exhibit provid
snapshot competit landscap exhibit walk result latest
survey exhibit appendix detail market product model
addit background cgrp market result survey last year refer
report specialti pharma cgrp primer market model cgrp market deep
dive post day new survey ahead
exhibit summari cgrp therapi market develop
survey neurologist collect see migrain patient per
month overal feedback posit cgrp market particularli allergan/abbvi
teva within coverag relev provid comparison prior
cgrp survey conduct april
drugcompanymodalityindicationdos methoddos frequencylaunch revenuecommentsaimovig erenumab amgn/nvsmabmigrain prophylaxissubcutan injectionmonthlymay first cgrp launch retain signific first-mov advantag though share gradual erodedajovi fremanezumab tevamabmigrain prophylaxissubcutan injectionmonthli quarterlysep market share hurt lack autoinjector teva expect launch one come month emgal galcanezumab llymabmigrain prophylaxissubcutan injectionmonthlyoct approv cgrp therapi episod cluster headach addit migrain preventioneptinezumabaldrmabmigrain prophylaxisintraven later game rel cgrp mab uniqu iv deliveri could carv nich marketubrelvi ubrogep agn/abbvsmal molecul antagonistacut migraineoraldailyjan first oral cgrp launch earli biohaven rimegep expect close behindatogepantagn/abbvsmal molecul antagonistmigrain run two separ ph studi episod migrain em chronic migrain cm well long-term safeti studyrimegepantbhvnsmal molecul antagonistacut use prioriti review voucher prv rimegep place pdufa pharmaceut new cgrp survey deep dive
exhibit result survey neurologist treat migrain
survey questionsresponsesfeb headach day per headach day per headach day per botox neither cgrp use expect total number patient treat botox migrain chang next month half respond expect stabl botox usag next month among remaind expect increas use botox migrain expect decreas use overal suggest stabl slightli outlook botox consist model number patient cgrp therapi exce botox migrain insignific percentag patient also plenti room growth half patient neither cgrp expect total number patient treat prevent cgrp therapi chang next month overal respond expect increas cgrp usag next month view overal cgrp market growth tailwind benefit market player notwithstand ebb flow market quantifi percentag total patient migrain place follow prevent therapi combin therapi roughli two-third patient treat episod migrain less headach day per month remaind chronic migrain headach day per size vari wide monthli patient number rang less way per quantifi percentag patient migrain averag mani patient migrain see per month patient per month pharmaceut new cgrp survey deep dive
exhibit result survey neurologist treat migrain cont
number factor go cgrp vs botox prescrib decis detail exhibit
cite efficaci patient prefer reimbursement/access
headach frequenc method administr also consid
survey questionsresponsesfeb ajovi pre-fil ajovi pre-fil ajovi autoinjector eptinezumab botox cgrp botox headach day per headach day per headach day per new oral cgrp therapi acut treatment migrain either avail ubrelvi expect becom avail soon rimegep clinic trial drug demonstr statist signific improv pain freedom hour initi dose ii absence/freedom bothersom symptom percentag patient type migrain like prescrib oral cgrp acut migrain physician view overal migrain patient like candid acut oral cgrp greatest use expect among chronic migrain patient model acut oral cgrp use among headach day per month popul mean could signific upsid forecast though survey bia reimburs challeng need account practic pleas rate level difficulti respect reimbursement/access follow therapi pleas rate scale difficult difficult applic pleas input zero physician rate reimbursement/access difficulti nearli three on-market cgrp mab well botox surprisingli reimbursement/access concurr use cgrp botox much difficult ajovi slightli emgal slightli latest iqvia trend would indic respons otherwis direct new cgrp therapi migrain prophylaxi expect becom avail soon autoinjector version ajovi eptinezumab quarterli anti-cgrp infus therapi one year pleas indic percent migrain patient treat prevent cgrp therapi expect place follow therapi launch ajovi autoinjector expect off-set pre-fil syring share loss result net bp increas market share ajovi despit expect launch eptinezumab year respond expect take share next new migrain patient prescrib prevent cgrp therapi percent place follow therapi pharmaceut new cgrp survey deep dive
exhibit result survey neurologist treat migrain physician feedback around prevent cgrp
physician base latest survey divers respect practic size
geographi shown exhibit total migrain patient number rang less
per month low end per month high end
abil function frequencyfailur medonc fail oral therapiesaccess se profileformul eas administr patientsoth med work botox failur frequenc intens headach previou fail medicationspati concern injectionbotox days/m pt preferencegood candidatespati preferencebotox hassl mani reasonsha frequenc associ disabl prior treatment etc patient preferencebotox invas like least invasivei dont refer ha center patient prefer cgrp conveni less discomfort patientsi use botoxpati prefer coverageimpress efficaci cgrp vs botox find pt satisfact far higher cgrppatient requestdiagnosi use cgrp med episod migrain botox chronic patient prefer also key improv efficaci favor safeti profil cgrp therapypati prefer type migrain presenc cervicalgiadon primarili treat itinject numberpeopl scare long term effect botox cardio toxicityeas conveni therapyinsur patient preferencereli eas administr work wellself administ less hassl geteasi patientlevel migrain controlsever frequenc attackseffect low risk easi prescribemagnitud inject vs frequenc greater botox patient set symptom agre upon profess effectivenessmechan actiontoler comorbid condit insur coverageeffect cgrpmigrain sever control comfort cgrpusual botox failur vs logist insur issuesefficaci regimen patient conveni minim use efficaci greatusu patient fail botox anti-cgrpefficaci safeti patient acceptancenew therapi cycl difficult control patient thru newer therapies/optionswork fast approv fail botox number inject pleas describ primari factor influenc decis prescrib prevent cgrp therapi versu botox migrain pharmaceut new cgrp survey deep dive
exhibit background detail neurologist divers term practic size locat
physician expect strong continu cgrp patient growth view around botox
mix exhibit depict patient growth expect therapi type
importantli growth cgrp market appear come expens
botox consist allergan messag said cgrp entri appear
slow botox migrain growth reflect botox model
roughli flat migrain compound-annual-growth-rate
exhibit expect cgrp botox patient growth
exhibit show actual expect prevent cgrp market share
per survey teva target market share ajovi post autoinjector
launch survey result help add credibl target said
like take time rebuild share especi given drop ajovi market share
seen earli
pharmaceut new cgrp survey deep dive
exhibit survey respond expect ajovi pre-fil syring autoinjector collect take share
prevent cgrp market month share today pre-fil syring
note ajovi autoinjector launch expect come month eptinezumab pdufa
survey respond appear rel open oral cgrp expect usag
migrain sever detail exhibit oral cgrp major focu survey
surpris rel high expect usag total migrain patient
though like survey bia factor could limit uptak practic includ class
safeti percept concern around efficacy/compli reimburs challeng
overal see import place market oral cgrp modestli
rais estim ubrelvi atogep
pharmaceut new cgrp survey deep dive
exhibit expect oral cgrp uptak acut migrain collect allergan ubrelvi
biohaven rimegep
pharmaceut new cgrp survey deep dive
appendix cgrp model pt updat compani ls
migrain patient patient actualactualest estimate estimate estimate estimate estimate estimate estimate commentstot us migrain patient us populationgrowth chronic migrain cm migrain total around thetot episod migrain em number studieschron migrain cm patient seek assum new therapi increas treatment ratescm patient patient treat patient non-respond triptanscm patient treat cm popul migrain em headach day per base ampp survey data patient poor treatment base ampp survey datatarget em popul headach day per base ampp survey data patient poor treatment base ampp survey datatarget em popul target popul chronic high-frequ em patientstot target popul em patient headach day per monthprophylact migrain market million actualactualest estimate estimate estimate estimate estimate estimate estimate commentstarget patient popul migrain patient buildmarket share target patient total market share cgrp captur cgrp migrain botox migrain modeltot cgrp botox durat use mab longer durat use less switch timetot via aldr acquisit atogep oral cgrp market share cgrp patient adjust quarterli aimovig oral migrain market million actualactualest estimate estimate estimate estimate estimate estimate estimate commentstarget patient popul migrain patient buildmarket share target patient ubrelvi cgrp market assum ubrelvi rimegep split marketpati captur jan pdufatot cgrp cgrp acut cgrp durat use longer durat use less switch time pharmaceut new cgrp survey deep dive
exhibit model peak us sale teva ajovi million
exhibit model peak us sale allergan ubrelvi ubrogep million
exhibit model peak us sale allergan atogep million prior risk-adjust
ajovi million actualest estimate estimate estimate estimate estimate estimate estimate commentstarget patient popul cgrp market modelgrowth patient sep market durat use cgrp market dose dose cgrp market modeltot monthli dose cost aimovig emgal price roughli paritypr growth steadi state remain swing factornet monthli ajovi sale sep growth ubrogep million actualactualest estimate estimate estimate estimate estimate estimate commentstarget patient popul cgrp market modelgrowth patient cgrp market model market durat use cgrp market modeltot month usemonthli cost medi-span price rxprice growth heavi sampl earli launchnet monthli ubrelvi sale guidanc oral cgrpsrevenu growth million actualest estimate estimate estimate estimate estimate estimate estimate commentstarget patient popul cgrp market modelgrowth patient market durat use month usemonthli cost initi price cgrp mabspric growth monthli atogep sale guidanc oral cgrpsrevenu growth studi ongoingrisk-adjust atogep sale launch pharmaceut new cgrp survey deep dive
rais price target reflect updat pro-forma
rais price target result chang pro-forma
abbvie/allergan forecast price target base equal ev/ebitda price-to-earnings
estim reflect close allergan acquisit use
multipl respect reflect meaning discount histor
industri averag adjust us loss exclus humira impli
return price target support sector perform rate make minor
adjust estim allergan teva due result survey model
previou pharmaceut new cgrp survey deep dive
exhibit allergan pro-forma model
forma incom million estimate estimate estimate estimate estimate estimate commentslegaci stand-alon modellegaci stand-alon modelless net product zenpep contributiongross profit cost synergi year oper incom expens foreign exchang incom expens interest expens incom tax tax earn ep share share per rate legaci legaci net profit analysi share per exhibit allergan
pharmaceut new cgrp survey deep dive
allergan incom gener us special total revenu good total gross profit oper incom reflect amort add-back per gener reportingoth incom expens incom tax provis incom net incom ep adjust dilut share dividend per ebitda analysi revenu net gross incom margin exhibit teva
pharmaceut new cgrp survey deep dive
teva incom segment restat effect growth restat begin revenu total revenu guid billioncost begin gross profit gener incom guid billionoth incom incom tax provis incom guid tax ratenet incom add-back prefer adjust net ep pro-forma guid dilut share guid million sharesebitda guid billion ebitda expens guid tax rateadjust net incom analysi net pharmaceut new cgrp survey deep dive
analyst respons prepar research report receiv compens base upon variou factor includ
total revenu member compani capit market affili portion gener
invest bank activ member compani capit market affili
pleas note current conflict disclosur may differ public date set forth
report access current conflict disclosur client refer http //www rbccm com/gldisclosure/publicweb/
send request cm research publish bay street royal bank plaza
member compani capit market one affili manag co-manag public offer secur
abbvi inc past month
member compani capit market one affili receiv compens invest bank servic
abbvi inc past month
capit market llc make market secur abbvi inc
member compani capit market one affili receiv compens product servic
invest bank servic abbvi inc past month time member compani capit
market one affili provid non-secur servic abbvi inc
capit market current provid abbvi inc non-secur servic
capit market provid abbvi inc invest bank servic past month
capit market llc make market secur allergan public limit compani
capit market llc make market secur teva pharmaceut industri limit
member compani capit market one affili receiv compens product servic
invest bank servic teva pharmaceut industri limit past month time member
compani capit market one affili provid non-secur servic teva pharmaceut industri limit
capit market current provid teva pharmaceut industri limit non-secur servic
explan capit market equiti rate system
analyst sector univers compani analyst provid research coverag accordingli rate assign
particular stock repres sole analyst view stock perform next month rel
top pick tp repres analyst best idea sector expect provid signific absolut total return month
favor risk-reward ratio
outperform expect materi outperform sector averag month
sector perform sp return expect line sector averag month
under-perform return expect materi sector averag month
restrict polici preclud certain type commun includ invest recommend
act advisor certain merger strateg transact certain circumst
rate nr rate price target estim remov due applic legal regulatori polici constraint
may includ capit market act advisori capac involv compani
specul risk rate reflect secur lower level financi oper predict illiquid share trade volum
high balanc sheet leverag limit oper histori result higher expect financi and/or stock price volatil
pharmaceut new cgrp survey deep dive
distribut rate
purpos rate distribut regulatori rule requir member firm assign rate one three rate categori
 buy hold/neutr sell regardless firm rate categori although capit market rate top pick/
outperform sector perform under-perform close correspond buy hold/neutr sell respect mean
rate determin rel basi
distribut rate
rate price target histori abbvi inc us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
pharmaceut new cgrp survey deep dive
rate price target histori allergan public limit compani agn us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
rate price target histori teva pharmaceut industri limit teva us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
refer recommend list recommend histori chart may includ one recommend list model
portfolio maintain wealth manag one affili wealth manag recommend list includ
guid portfolio prime incom rl guid portfolio dividend growth rl guid portfolio adr rl
guid portfolio cap growth rl capit market recommend list includ strategi focu list
fundament equiti weight portfolio abbrevi rl mean date secur place
recommend list abbrevi rl mean date secur remov recommend list
equiti valuat risk
valuat method use determin risk may imped achiev price target cover compani pleas
see recent company-specif research report http //www rbcinsightresearch com send request capit
pharmaceut new cgrp survey deep dive
price target base equal ev/ebitda price-to-earnings estim reflect close allergan
acquisit use multipl respect reflect meaning discount histor industri averag
adjust us loss exclus humira impli return price target support sector perform rate
risk rate price target
risk rate price target includ limit tail valu risk humira still meaning contributor
combin compani acquisit risk work close integr allergan transact largest deal
histori regulatory/polit risk broadli applic sector particularli around pricing/reimburs
price target reflect offer cash share current trade price per share
impli ep estim stand-alone estim reflect single-digit ep growth forecast lack
meaning near-term catalyst drive upsid price target impli return support sector perform rate
risk rate price target
risk price target rate includ limit inabl convert pipelin product competit key
product prove intens model activist pressur
price target base equal price-to-earnings ev/ebitda reflect teva moder lower tax rate current leverag
price target base multipl respect result gener valuat framework
reflect uniqu fundament risk current environ particularli around opioid uncertainti ii uncertainti
around addit gener copaxon launch iii brand pipelin without risk iv leverag risk
risk rate price target
follow could lead teva realiz downsid price target rate slower expect sale ramp ajovi
austedo higher expect top-lin impact base busi aggress cost cut continu price pressur
multipl addit gener copaxon launch weak cash flow gener jeopard debt pay-down
coven complianc uncertainti around potenti liabil associ opioid gener price fix litig
capit market polici manag conflict interest relat invest research avail us request
access current polici client refer
send request capit market research publish bay street royal bank plaza floor south
tower toronto ontario reserv right amend supplement polici time
dissemin research short-term trade idea
capit market endeavor make reason effort provid research simultan elig client
regard local time zone oversea jurisdict capit market equiti research post proprietari websit
ensur elig client receiv coverag initi chang rate target opinion time manner addit
pharmaceut new cgrp survey deep dive
distribut may done sale personnel via email fax electron mean regular mail client may also
receiv research via third parti vendor capit market also provid elig client access sparc firm
proprietari insight websit via email via third-parti vendor sparc contain market color commentari regard
subject compani firm current provid equiti research coverag research analyst may time time
includ short-term trade idea research report sparc short-term trade idea offer short-term view
secur may trade base market trade event result trade opportun may avail
short-term trade idea may differ price target recommend publish research report reflect
research analyst view long-term one year prospect subject compani result differ time horizon
methodolog and/or factor thu possibl subject compani common equiti consid long-term
sector perform even under-perform might present short-term buy opportun result temporari sell pressur
market convers subject compani common equiti rate long-term outperform could consid suscept
short-term downward price correct short-term trade idea rate part rate system
firm gener intend undertak oblig maintain updat short-term trade idea short-term trade
idea may suitabl investor tailor individu investor circumst object
investor make independ decis regard secur strategi discuss herein pleas contact
invest advisor institut salesperson inform regard capit market research
list recommend compani dissemin prior period pleas click
month histori sparc view http //www rbcinsightresearch com
view express report accur reflect person view respons analyst
subject secur issuer part compens respons analyst name herein directli
indirectli relat specif recommend view express respons analyst report
global industri classif standard gic develop exclus properti servic mark inc standard poor financi servic
llc licens use neither parti involv make compil gic gic classif make express impli
warranti represent respect standard classif result obtain use thereof parti herebi expressli disclaim warranti
origin accuraci complet merchant fit particular purpos respect standard classif without limit forego
event shall affili third parti involv make compil gic gic classif liabil direct indirect special
punit consequenti damag includ lost profit even notifi possibl damag
refer herein libor libo rate libor abbrevi mean london interbank offer rate administ benchmark administr
person take administr rate
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict capit
market may restrict publish research report time time due regulatori restrict and/ intern complianc polici case
latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject compani
capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri busi
secur broker dealer jurisdict full extent permit law neither capit market affili person accept
liabil whatsoev direct indirect consequenti loss aris connect use report inform contain herein
matter contain document may reproduc copi mean without prior written consent capit market instanc
addit inform avail request
pharmaceut new cgrp survey deep dive
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
